Literature DB >> 19139826

Meningeal carcinomatosis in HER2-overexpressing breast cancers.

F C Bidard, M N Guilhaume, H Gauthier, P H Cottu, V Diéras, J Y Pierga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19139826     DOI： 10.1007/s11060-008-9768-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  4 in total

1.  High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer.

Authors:  O Mir; S Ropert; J Alexandre; F Lemare; F Goldwasser
Journal:  Ann Oncol       Date:  2008-10-09       Impact factor: 32.976

Review 2.  Neoplastic meningitis.

Authors:  Marc C Chamberlain
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

3.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group.

Authors:  S A Grossman; D M Finkelstein; J C Ruckdeschel; D L Trump; T Moynihan; D S Ettinger
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

4.  Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen.

Authors:  K Fizazi; B Asselain; A Vincent-Salomon; M Jouve; V Dieras; T Palangie; P Beuzeboc; T Dorval; P Pouillart
Journal:  Cancer       Date:  1996-04-01       Impact factor: 6.860
  4 in total
  1 in total

1.  HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis.

Authors:  Anders W Erickson; Farinaz Ghodrati; Steven Habbous; Katarzyna J Jerzak; Arjun Sahgal; Manmeet S Ahluwalia; Sunit Das
Journal:  Neurooncol Adv       Date:  2020-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.